Molbio Diagnostics IPO: GMP, Price, Review and Details

Molbio Diagnostics IPO Date, Price, GMP, Review and Details: check ₹768-₹807 price band, ₹939.70 crore issue, subscription, valuation, risks and listing date.

Molbio Diagnostics IPO: What Investors Need to Know

Molbio Diagnostics Limited is attracting strong investor attention with its ₹939.70 crore initial public offering. The IPO opened for subscription on August 10, 2026, and will close on August 12, 2026. The price band has been fixed at ₹768 to ₹807 per equity share, while the minimum lot size is 18 shares.

As of 11 August 2026 at 1:30 PM, the issue was subscribed 1.84 times based on the subscription figures provided for this analysis. The Qualified Institutional Buyers portion was subscribed 1.01 times, the Non-Institutional Investor category 2.50 times, retail investors 2.03 times and employees 3.49 times.

The IPO has also been trading at a premium in the unofficial grey market. Market reports on August 11 placed the GMP around ₹122 to ₹127 per share, although the figure has been moving during the day. At a GMP of ₹127, the implied price works out to around ₹934, compared with the upper IPO price of ₹807. Grey market premiums are unofficial and should not be treated as a guaranteed listing price.

The bigger question for investors is different: Is Molbio Diagnostics worth subscribing to at the upper price band after considering its growth, profitability, valuation, business concentration and risks?

A detailed review of the company’s Red Herring Prospectus gives a mixed but interesting picture. Molbio has a differentiated point-of-care molecular diagnostics platform, recurring test-kit revenue, substantial R&D investment and a growing product portfolio. At the same time, the company remains heavily dependent on government and aid-agency programmes, tuberculosis testing and a relatively small group of customers.

Molbio Diagnostics IPO Details

The RHP confirms that the issue consists of a fresh issue of up to ₹200 crore and an Offer for Sale of up to 91.66 lakh shares. The company will receive the proceeds from the fresh issue, while the OFS proceeds will go to the selling shareholders.

Molbio Diagnostics IPO Subscription Status

The issue has seen healthy demand across investor categories.

The subscription numbers indicate that demand has already crossed the total shares available for the issue. QIB participation is important because institutional demand often becomes a key factor during the final phase of a mainboard IPO.

Independent market reports also showed strong demand during the second day of bidding. LiveMint reported subscription above 1.75 times around 1 PM, while the Economic Times reported that the issue had received 83% subscription on the first day.

Molbio Diagnostics IPO GMP Today

The Molbio Diagnostics IPO GMP has remained positive ahead of the issue closing.

On August 11, IPO Watch reported a GMP of ₹127 at 9:52 AM, while LiveMint reported around ₹124 later in the morning. Economic Times reported a GMP of approximately ₹122 around 12:40 PM. These differences show why GMP should be treated as a moving indicator rather than a fixed number.

At different GMP levels, the indicative listing calculation looks like this:

These are mathematical indications based on the grey market premium. They are not listing-price forecasts.

The company itself has clearly stated in its RHP that there was no formal market for its shares before the IPO and that the offer price should not be considered an indication of the eventual market price after listing.

Molbio Diagnostics IPO Review

What Does Molbio Diagnostics Do?

Molbio Diagnostics is a point-of-care molecular diagnostics company founded in 2000. Its flagship product is the Truenat platform, a portable molecular diagnostic system designed to bring PCR-based testing closer to patients and healthcare facilities.

The platform includes the Trueprep nucleic acid extraction device, Truelab real-time PCR analysers and disease-specific Truenat test kits.

The company operates across molecular diagnostics and has also expanded into radiology and digital pathology through subsidiaries and acquisitions.

The RHP describes Truenat as a portable and battery-operated point-of-care PCR platform. It is designed for locations where conventional laboratory infrastructure, electricity, space and specialised personnel may be limited. The company states that the platform can deliver results in approximately 60 minutes compared with conventional testing methods that often require substantially longer turnaround times.

As of March 31, 2026, Molbio had commercialised tests covering 30 diseases through 43 assays, compared with 30 diseases and 42 assays in FY25.

Why Truenat Matters to the Molbio Business Model

The most important feature of Molbio’s business model is the relationship between diagnostic devices and test kits.

The company sells the diagnostic devices, but a significant part of its revenue comes from the recurring sale of test kits.

This creates a model where an installed device has the potential to generate additional revenue through repeated testing.

The numbers in the RHP show how important this model has become.

Test-kit revenue increased sharply from ₹552.55 crore in FY24 to ₹1,034.82 crore in FY26. The company sold 17.56 million test kits in FY26 compared with 12.24 million in FY25 and 8.80 million in FY24.

This is one of the strongest parts of the Molbio investment story.

Molbio Diagnostics Financial Performance

The company’s financial performance has improved significantly over the last three financial years.

The financial figures are from the company’s RHP KPI section.

Revenue from operations grew from ₹836.56 crore in FY24 to ₹1,445.69 crore in FY26. That represents strong growth over two years.

Profit also increased from ₹83.54 crore to ₹164.14 crore during the same period.

However, the FY26 numbers also highlight an important issue. EBITDA margin declined from 24.97% in FY25 to 22.56% in FY26. Profit margin also declined from 13.48% to 11.28%.

Therefore, the revenue growth story is stronger than the margin expansion story.

EBITDA and R&D Analysis

Molbio’s R&D spending is an important part of its business model.

The company spent ₹87.46 crore on R&D in FY26 compared with ₹68.57 crore in FY25 and ₹59.78 crore in FY24.

The RHP reports FY26 EBITDA of ₹328.24 crore and EBITDA before R&D of ₹415.70 crore.

The RHP specifically cautions that EBITDA and related measures are non-GAAP measures and should not be viewed in isolation from Ind AS financial information.

The company had 153 permanent R&D employees as of March 31, 2026, compared with 114 in FY25 and 69 in FY24.

This increasing R&D base is relevant because the long-term investment case depends on expanding the test menu and commercialising new assays.

Molbio Diagnostics Test Kit Business

Test kits have become the core revenue engine.

In FY26, test-kit sales generated ₹1,034.82 crore, representing nearly 74% of revenue from the sale of finished goods.

The concern is the high dependence on tuberculosis-related products.

The RHP shows that TB test kits accounted for 96.02% of all test-kit units sold in FY26.

This is both a strength and a risk.

The strength is clear. Molbio has built a large business around TB diagnostics.

The risk is concentration. If TB testing volumes decline, government programmes change, alternative technologies gain acceptance or procurement policies change, the company’s test-kit revenue could be affected.

The company itself identifies this dependency as a material risk in the RHP.

Government Revenue Dependency

Another major issue is customer composition.

Molbio generated 84.56% of finished-goods revenue from Indian Central and State governments and international aid agencies in FY26.

The number was 87.83% in FY25 and 91.60% in FY24.

The RHP states that government and international aid agencies contributed ₹1,182.88 crore of finished-goods revenue in FY26.

This dependency needs careful consideration.

Government healthcare spending can create large volumes for diagnostic companies. At the same time, tender cycles, procurement decisions, programme priorities, payment cycles and public-health budgets are outside the company’s direct control.

Top Customer Concentration

Molbio also has significant customer concentration.

Its top 10 customers contributed 83.26% of finished-goods revenue in FY26.

This figure was 83.62% in FY25 and 78.54% in FY24.

This means investors should not evaluate Molbio only on its technology.

The ability to retain large government and institutional customers and continue receiving purchase orders is equally important.

The company has also stated that customer purchase orders are placed periodically rather than through firm long-term commitments in many cases. Its revenues and cash flows have historically fluctuated based on the timing and volume of orders.

Manufacturing Capacity

Molbio has six manufacturing facilities in India.

The facilities are located across Goa, Bengaluru, Visakhapatnam and Pune.

The company had installed capacity of:

• 5,400 devices per year
• 3.90 crore Truenat test kits per year

In FY26, device capacity utilisation was 42.30%, while test-kit capacity utilisation was 58.25%.

This leaves room for higher utilisation without requiring a complete new manufacturing network.

The IPO’s fresh issue is also targeted toward additional infrastructure and equipment.

How Molbio Diagnostics Will Use IPO Funds

The ₹200 crore fresh issue is intended for capital expenditure and general corporate purposes.

The major projects include a new R&D facility and Centre of Excellence operated by Bigtec, along with manufacturing equipment for Goa and Visakhapatnam.

The RHP estimates the total project cost for the R&D facility and connected office infrastructure at ₹125.12 crore, with ₹105.54 crore proposed to be financed from net IPO proceeds.

For plant, machinery and equipment at Goa Unit I, Goa Unit II and Visakhapatnam, the estimated project cost is ₹80.81 crore, with ₹72.28 crore proposed to be funded from net proceeds.

Therefore, the fresh issue is largely growth-oriented.

It is important to note that the IPO proceeds are not primarily being raised to repay debt.

The Economic Times also reported that the fresh issue is intended for R&D and manufacturing expansion rather than debt reduction.

R&D Centre Could Be an Important Trigger

Molbio’s existing R&D operations are conducted through Bigtec.

The company plans to establish a dedicated R&D facility and Centre of Excellence.

This could become important because the company’s long-term growth depends on adding new tests and assays.

The RHP states that the company plans to expand its menu of tests and that delays in product development or regulatory approvals could affect future revenue growth.

The proposed R&D facility is therefore more than a normal administrative expansion. It is linked to the company’s product pipeline.

Molbio Diagnostics IPO Valuation

Valuation is one of the most important sections of this IPO review.

At the upper price band of ₹807, Molbio’s FY26 diluted EPS is ₹14.77.

This gives an implied P/E of:

₹807 ÷ ₹14.77 = approximately 54.63 times

The RHP reports FY26 diluted EPS of ₹14.77 and a net asset value of ₹101.51 per share.

Based on these numbers:

P/E at ₹807 = about 54.6x

Price-to-book based on NAV = about 7.95x

The company’s RHP peer comparison shows the following FY26 P/E ratios:

The company reported a FY26 Return on Net Worth of 14.55% and NAV per share of ₹101.51.

At approximately 54.6x earnings, Molbio is not a cheap IPO in absolute terms.

The argument in favour of the valuation is its differentiated molecular diagnostics platform, recurring consumables revenue, R&D capability and growth opportunity.

The argument against it is that investors are already paying a significant premium for future growth.

Molbio Diagnostics vs Listed Peers

The company’s RHP compares Molbio with Poly Medicure, Dr Lal PathLabs, Metropolis Healthcare and Vijaya Diagnostics.

The comparison shows an important point.

Molbio’s FY26 revenue of ₹1,445.69 crore is below the revenue of most of these listed peers. Its business model is also different because a substantial part of its revenue comes from molecular diagnostics devices and consumables rather than conventional pathology services.

The RHP reports FY26 revenue, EPS, P/E, RONW and NAV for the peer group.

This makes direct P/E comparison useful but not sufficient.

Investors should also consider:

Recurring test-kit revenue

R&D intensity

Government exposure

Product concentration

International expansion

Regulatory approvals

Capacity utilisation

Return ratios

On these parameters, Molbio has a different investment profile from traditional diagnostic chains.

Molbio Diagnostics IPO Strengths

1. Differentiated Truenat Platform

The Truenat platform is the company’s biggest competitive asset.

It combines portability, battery operation and molecular testing capabilities for multiple diseases.

The RHP states that the platform has been designed for point-of-care and resource-constrained environments.

2. Recurring Test Kit Revenue

Test kits generated ₹1,034.82 crore in FY26.

The growth in test-kit sales is considerably stronger than device revenue growth. This supports the company’s recurring-revenue model.

3. Strong R&D Investment

R&D expenditure increased from ₹59.78 crore in FY24 to ₹87.46 crore in FY26.

The R&D team increased from 69 employees to 153 during the same period.

4. Growing Test Menu

The company had 30 commercialised diseases and 43 commercialised assays as of FY26.

5. Expansion Beyond Molecular Diagnostics

Through subsidiaries, Molbio has expanded into radiology and digital pathology.

The RHP identifies Prognosys Medical Systems and OptraScan as material subsidiaries. OptraScan became a subsidiary with effect from November 1, 2025.

6. Capacity Headroom

Test-kit capacity utilisation was 58.25% in FY26, leaving scope to increase production from existing capacity.

Molbio Diagnostics IPO Risks

1. High TB Dependence

TB test kits accounted for 70.20% of finished-goods revenue and 96.02% of test-kit units sold in FY26.

This is one of the biggest risks in the business model.

2. Government and Aid Agency Dependence

Government and international aid agencies generated 84.56% of finished-goods revenue in FY26.

Changes in healthcare programmes, government procurement, tender activity or funding could affect sales.

3. Customer Concentration

The top 10 customers contributed 83.26% of finished-goods revenue in FY26.

A loss of a major customer or reduction in purchase orders could have a significant financial impact.

4. Margin Pressure

EBITDA margin declined from 24.97% in FY25 to 22.56% in FY26.

Profit margin also declined from 13.48% to 11.28%.

5. High Valuation

At ₹807, the IPO implies approximately 54.6 times FY26 earnings based on the RHP’s ₹14.77 diluted EPS.

The valuation leaves less room for disappointment if future earnings growth slows.

6. Working Capital and Cash Flow Volatility

Operating cash flow was ₹50.39 crore in FY26 compared with ₹287.10 crore in FY25.

The decline is significant despite higher profit.

The RHP attributes part of the FY26 operating cash flow dynamics to working capital movements and other adjustments.

7. Borrowings

As of May 31, 2026, consolidated outstanding borrowings stood at ₹422.50 crore.

This does not automatically make the company financially weak, but investors should track debt, finance costs and cash generation after listing.

8. Regulatory Risk

Medical diagnostics is a heavily regulated industry.

The company states that its products and manufacturing facilities are subject to regulatory requirements and inspections. Failure to maintain approvals or comply with applicable regulations could lead to penalties, restrictions, recalls or delays.

9. Imported Raw Materials

Molbio imported raw materials worth ₹243.40 crore in FY26, representing 42.01% of raw material and component consumption.

Changes in import duties, currency rates, trade policies or supply availability could affect costs.

10. Technology and Competition

The molecular diagnostics industry changes rapidly.

The company itself notes that larger competitors could have stronger financial resources, manufacturing capacity, R&D capabilities, regulatory experience and geographical reach.

Cash Flow Analysis

Cash flow deserves special attention in the Molbio IPO.

The FY26 closing cash position improved sharply, but operating cash generation was considerably lower than FY25.

This is an area investors should monitor after listing because sustained earnings growth without corresponding operating cash flow would require closer working-capital analysis.

Legal and Corporate Governance Considerations

The RHP contains disclosures relating to legal, regulatory and compliance matters.

For example, the parent company paid ₹4.52 crore in connection with an income-tax survey as of March 31, 2026 and subsequently paid another ₹3.37 crore after the financial year ended. Management has stated that it expects a favourable outcome.

The RHP also discloses previous compliance matters involving Section 135 of the Companies Act and Section 185 in relation to Bigtec, with penalties paid and matters addressed as disclosed in the document.

These disclosures do not by themselves determine the IPO’s investment quality, but they are part of the due-diligence process and should not be ignored.

Molbio Diagnostics IPO: Long-Term Investment View

From a long-term business perspective, Molbio has several qualities that make the IPO interesting.

The company has developed its own diagnostic platform rather than operating only as a conventional pathology chain.

The recurring test-kit model is another positive factor.

The expansion of commercialised assays, investment in R&D and planned Centre of Excellence could support future growth.

The company also has opportunities beyond TB. Its portfolio includes tests related to hepatitis, influenza, dengue, COVID-19, HPV and other diseases, while the company is working on additional assays.

The industry itself also has a structural growth opportunity. The RHP cites a 1Lattice report projecting the global molecular diagnostics market to grow from USD 19.8 billion in calendar 2025 to USD 31.1 billion by calendar 2030, a CAGR of 9.4%. However, the RHP also warns that this market data comes from a commissioned report and investors should not rely on it alone for an investment decision.

The weakness is valuation.

At around 54.6x FY26 earnings, the IPO is priced for meaningful future growth. At the same time, FY26 EBITDA margin and profit margin declined from FY25 levels.

The high concentration in TB testing and government customers adds another layer of risk.

Molbio Diagnostics IPO Review: Should You Subscribe?

A research-style conclusion would be more nuanced than simply calling the IPO “good” or “bad.”

For short-term listing investors, the positive GMP and strong subscription figures are supportive. The current grey market premium indicates that market participants expect the shares to list above the upper price band. However, GMP is unofficial and has already moved significantly in a few days. IPO Watch showed the GMP falling from ₹220 on August 7 to ₹127 on August 11.

For long-term investors, the business case is more important than the GMP.

Molbio has a differentiated product, strong test-kit growth, growing R&D capabilities and an established presence in point-of-care molecular diagnostics.

At the same time, investors are paying a premium valuation for those strengths. The company has high exposure to government healthcare programmes, TB testing and a concentrated customer base. Operating cash flow also requires monitoring.

A reasonable research conclusion is therefore:

Molbio Diagnostics IPO appears fundamentally interesting for investors with a long-term view, but the valuation is not inexpensive. Investors should focus on future earnings growth, margin stability, diversification beyond TB, customer diversification and operating cash flow rather than relying on GMP-driven listing expectations.

This is an analytical assessment based on the RHP, current subscription information and market reports. It is not a personal investment recommendation.

Molbio Diagnostics IPO Important Dates

The RHP confirms the public bidding period from August 10 to August 12, while current market reports also point to August 17 as the expected listing date.

Molbio Diagnostics IPO Application Amount

Retail investors can apply for one lot of 18 shares.

At the lower price band:

18 × ₹768 = ₹13,824

At the upper price band:

18 × ₹807 = ₹14,526

Therefore, investors applying at the upper price band need approximately ₹14,526 for one retail lot.

The RHP also provides separate application categories for retail investors, non-institutional investors and eligible employees.

FAQ

Final Conclusion

The Molbio Diagnostics IPO offers exposure to India’s point-of-care molecular diagnostics segment through a business built around the Truenat platform and recurring test-kit sales.

The company’s revenue increased from ₹836.56 crore in FY24 to ₹1,445.69 crore in FY26, while profit for the year increased from ₹83.54 crore to ₹164.14 crore. Test-kit revenue more than doubled over the same period.

The key attraction is the combination of proprietary diagnostics technology, recurring consumables, R&D investment and potential expansion into new disease areas.

The key concern is valuation and concentration. About 70.20% of finished-goods revenue came from TB test kits in FY26, 84.56% came from government and international aid agencies, and the top 10 customers contributed 83.26% of finished-goods revenue.

For investors evaluating the IPO beyond listing gains, future earnings growth, margin recovery, diversification beyond TB, broader customer adoption and operating cash flow will be the numbers to watch after listing.

Important: IPO GMP is an unofficial market indicator. The company’s RHP also states that SEBI has not approved or recommended the securities and does not guarantee the accuracy or adequacy of the prospectus contents. Investors should read the complete RHP and assess their own risk before making an investment decision.